Johnson & Johnson has provided the first healthcare venture group investment in the Vivo Capital Fund VIII that aims to help US and Chinese businesses work cross-border.
Johnson & Johnson Development Corporation (JJDC), the corporate venturing subsidiary of pharmaceutical company Johnson & Johnson, has invested $15m in the Vivo Capital Fund VIII managed by US-based healthcare investment firm Vivo Capital.
This is the first investment by a healthcare venture group in the fund. The investment is to be used both in the US and China to provide late-stage venture capital and early-stage stage growth capital to companies.
Vivo Capital announced the final close of the Vivo Capital…
